83 related articles for article (PubMed ID: 6469433)
1. Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.
Elliott HL; Meredith PA; Howden CW; Lawrie CB; Reid JL
Int J Clin Pharmacol Res; 1984; 4(1):61-9. PubMed ID: 6469433
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
Elliott HL; Meredith PA; Reid JL
J Hypertens Suppl; 1984 Dec; 2(3):S551-4. PubMed ID: 6599716
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.
Meredith PA; Elliott HL; McSharry DR; Kelman AW; Reid JL
Br J Clin Pharmacol; 1983 Jul; 16(1):27-32. PubMed ID: 6882620
[TBL] [Abstract][Full Text] [Related]
4. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
Salzmann R; Gerber W; Pally C; Scholtysik G
J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL
Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of once daily endralazine in hypertension.
Wu R; Spence JD; Carruthers SG
Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143
[TBL] [Abstract][Full Text] [Related]
7. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine.
Kindler J; Rüegg PC; Neuray M; Pacha W
Eur J Clin Pharmacol; 1987; 32(4):367-72. PubMed ID: 3609114
[TBL] [Abstract][Full Text] [Related]
8. Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
Kirch W; Axthelm T
J Cardiovasc Pharmacol; 1982; 4(4):562-6. PubMed ID: 6181329
[TBL] [Abstract][Full Text] [Related]
9. [Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)].
Kindler J; Glöckner WM; Sieberth HG; Konrads A; Meurer KA; Schulz V; Vaith P
Dtsch Med Wochenschr; 1981 Sep; 106(37):1176-81. PubMed ID: 7343274
[TBL] [Abstract][Full Text] [Related]
10. [Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
Hartmann HG; Schumacher H
Schweiz Med Wochenschr; 1985 Jul; 115(27-28):939-44. PubMed ID: 2862703
[TBL] [Abstract][Full Text] [Related]
11. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
[TBL] [Abstract][Full Text] [Related]
12. Acute haemodynamic effects of endralazine in patients with coronary artery disease and stable angina pectoris.
van der Wall EE; de Feyter PJ; Res JC; Roos JP; van Engelen CL
Postgrad Med J; 1983; 59 Suppl 3():42-4. PubMed ID: 6647210
[TBL] [Abstract][Full Text] [Related]
13. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure.
Quyyumi AA; Wagstaff D; Evans TR
Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162
[TBL] [Abstract][Full Text] [Related]
14. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123
[TBL] [Abstract][Full Text] [Related]
15. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.
Bogers WA; Meems L
Eur J Clin Pharmacol; 1983; 24(3):301-5. PubMed ID: 6861845
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats.
Orallo F
Br J Pharmacol; 1997 Aug; 121(8):1627-36. PubMed ID: 9283696
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment.
Elliott HL; Meredith PA; Sloan L; Reid JL
Eur J Clin Pharmacol; 1984; 27(2):159-63. PubMed ID: 6499896
[TBL] [Abstract][Full Text] [Related]
19. Acute hypotensive, hemodynamic effects of long-term treatment with niludipine, a Ca2+-antagonist, in patients with essential hypertension. Niludipine monotherapy and combination with a beta-blocker and a diuretic).
Aoki K; Sato K
Arzneimittelforschung; 1982; 32(9):1141-5. PubMed ID: 6756418
[TBL] [Abstract][Full Text] [Related]
20. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
